A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

ClinicalTrials.gov ID: NCT07409272

Public ClinicalTrials.gov record NCT07409272. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 6, 2026, 7:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ASP3082 in Combination With mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants With KRAS G12D Mutated Metastatic Pancreatic Adenocarcinoma

Study identification

NCT ID: NCT07409272
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Enrollment: 614 participants

Conditions and interventions

Conditions

Interventions

Irinotecan Drug
Leucovorin Drug
Oxaliplatin Drug
Placebo Drug
Setidegrasib Drug
fluorouracil Drug
liposomal irinotecan Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 16, 2026
Primary completion: Aug 30, 2029
Completion: Aug 30, 2029
Last update posted: Apr 15, 2026

2026 – 2029

United States locations

U.S. sites: 12
U.S. states: 8
U.S. cities: 12

Facility	City	State	ZIP	Site status
Crosson Cancer Institute at Providence St. Jude Medical Center in Fullerton	Fullerton	California	92835	Recruiting
Baptist MD Anderson Cancer Institute	Jacksonville	Florida	32207	Recruiting
Saint Elizabeth Medical Center, Inc. DBA St. Elizabeth Health Care	Edgewood	Kentucky	41017	Recruiting
HealthPartners Frauenshuh Cancer Center	Saint Louis Park	Minnesota	55426	Recruiting
HealthPartners Cancer Center at Regions Hospital	Saint Paul	Minnesota	55101	Recruiting
NYU Long Island Mineola	Mineola	New York	11501	Recruiting
Laura and Isaac Perlmutter Cancer Center at NYU Langone	New York	New York	10016	Recruiting
White Plains Hospital Center for Cancer Care - Oncology	White Plains	New York	10601	Recruiting
Utah Cancer Specialists	Salt Lake City	Utah	84106	Recruiting
UVA Emily Couric Cancer Center	Charlottesville	Virginia	22903	Recruiting
Virginia Cancer Specialists	Fairfax	Virginia	22031	Recruiting
Virginia Mason Franciscan Health - Virginia Mason Medical Center	Seattle	Washington	98101	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07409272, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 15, 2026 · Synced May 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07409272 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →